Selegiline's neuroprotective capacity revisited.
Riederer
P
P
Clinical Neurochemistry, Clinic and Policlinic for Psychiatry and Psychotherapy, University of Wuerzburg, Germany. peter.riederer@mail.uni-wuerzburg.de
Lachenmayer
L
L
D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000201:enzymology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D006801:Humans; D008995:Monoamine Oxidase / Q000187:drug effects / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; D012642:Selegiline; D008995:Monoamine Oxidase